Compare Becton Dickinson and Co (BDX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs PepsiCo, Inc. — how do they compare? Becton Dickinson and Co trades at $155.64 (market cap $41.51B), while PepsiCo, Inc. trades at $135.57 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 4.5× Becton Dickinson and Co's market cap, and PepsiCo, Inc. pays the higher dividend (4.37%). Which is the better fit depends on your goals.
| BDX | PEP | |
|---|---|---|
Market Cap | $41.51B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $170.44 |
52-Week Low | $135.49 | $133.81 |
Enterprise Value | $57.97B | $227.37B |
Dividend Yield | 2.79% | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
PepsiCo (PEP) trades at $135.11, down 2.44% over the past day, with a bearish technical outlook. The stock shows strong profitability with a 10.78% net income margin and 51.59% ROE, though revenue growth remains modest. Recent earnings have consistently beaten estimates, and the company maintains a solid dividend. However, price pressures on snacks and high debt levels pose challenges. Analyst consensus is a 'Hold' with a $159.27 price target, indicating potential upside from current levels.
The outlook for PEP is mixed: fundamentals are robust with earnings beats and high returns, but technicals and sentiment are cautious. Investment opportunity lies in valuation discount to analyst targets and dividend yield, while risks include consumer pushback on pricing, competitive pressures, and leverage. Near-term performance hinges on Q3 2026 earnings and North American segment recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
